Home › Hemophilia › Georgia › Atlanta
Hemophilia clinical trials in Atlanta, GA
4 studies for Hemophilia are looking for participants at sites in and around Atlanta (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Treatment of Hemophilia A Patients With FVIII Inhibitors
RecruitingObservational study
- Arthur M. Blank Hospital, Atlanta
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
RecruitingPhase 3
- Children's Healthcare of Atlanta, Atlanta
- Emory University Hospital, Atlanta
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
- Comprehensive Bleeding Disorders Center at Emory University and Children's Healthcare of Atlanta, Atlanta
- Emory/Children's Health Care of Atlanta, Atlanta
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
RecruitingPhase 4
- Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory, Adult Division, Atlanta
About Hemophilia
Hemophilia is a rare disorder in which the blood does not clot normally. Usually hemophilia usually occurs in males and is inherited. Learn more.
More about Hemophilia on MedlinePlus
Hemophilia trials in other cities
- Indianapolis, IN9 studies
- Los Angeles, CA7 studies
- Seattle, WA6 studies
- Cedar Rapids, IA6 studies
- Philadelphia, PA5 studies
- Tampa, FL4 studies
- Sacramento, CA4 studies
- Little Rock, AR4 studies
- Dallas, TX4 studies
- Greenville, NC4 studies
- Orange, CA4 studies
- San Francisco, CA3 studies
Other studies in Atlanta
- Cancer (all types)49 studies
- Non-Small Cell Lung Cancer47 studies
- Breast Cancer41 studies
- Multiple Myeloma41 studies
- Prostate Cancer33 studies
- Acute Myeloid Leukemia30 studies
- Ovarian Cancer29 studies
- Lung Cancer29 studies
- Colorectal Cancer29 studies
- Metastatic Cancer28 studies
- Heart Failure25 studies
- Major Depressive Disorder25 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.